Skip to main content

Evolution of Adaptive Immunity in Vertebrates

October 2, 2019 - 3:00pm to 4:00pm
Max D. Cooper, M.D., Emory University School of Medicine

Phylogenetic studies indicate that T cells and B cells have been constant companions in vertebrates for more than 500 million years. For antigen recognition, however, lymphocytes in the jawless vertebrates (lampreys and hagfish) use variable lymphocyte receptors that are composed of leucine-rich repeat sequences instead of immunoglobulin V(D)J and C domains. Convergent evolution may account for these alternative solutions to achieve specific adaptive immunity.

Brain Machine Interfaces: from Basic Science to Neuroprostheses and Neurological Recovery

October 16, 2019 - 3:00pm to 4:00pm
Miguel A. Nicolelis, M.D., Ph.D., Duke University Medical Center

“In this talk, I will describe how state-of-the-art research on brain–machine interfaces makes it possible for the brains of primates to interact directly and in a bi-directional way with mechanical, computational and virtual devices without any interference of the body’s muscles or sensory organs. I will review a series of recent experiments using real-time computational models to investigate how ensembles of neurons encode motor information.

Scalable Platforms for Generating RNA Sensors and Controllers

October 23, 2019 - 3:00pm to 4:00pm
Christina D. Smolke, Ph.D., Stanford University

Whether animals are looking for food or mates, or avoiding pathogens and predators, they rely on biosensors—molecules that allow animals to sense and respond to their environments. Creating new kinds of biosensors to receive, process, and transmit molecular information is the focus of Dr. Smolke’s research. Her innovative approaches for designing biomolecules have applications in diagnostics, drug development, green chemistry, and more. Her lab has created RNA molecules, or switches, that can detect the disease state of a cell.

PROTAC-Mediated Protein Degradation: a New Therapeutic Modality

November 6, 2019 - 3:00pm to 4:00pm
Craig M. Crews, Ph.D., Yale University

The ability to control protein levels using PROTACs is changing how drugs are being developed and is expanding our concept of the druggable target space. Moreover, PROTACs offer the advantages of siRNA but with more favorable pharmaceutical properties (ADME, biodistribution, routes of administration). For the past 20 years, Dr. Crews has pioneered the development of this new modality from concept to clinical trials. Here he will describe the current and future trends in this fast-paced, exciting new therapeutic field.

Bad Deeds Go Unpunished: The Vacuole Guard Hypothesis and Pathogen Intracellular Growth

November 20, 2019 - 3:00pm to 4:00pm
Ralph R. Isberg, Ph.D., Tufts University School of Medicine

Intravacuolar bacterial pathogens establish intracellular niches by constructing membrane-encompassed compartments. The vacuoles surrounding the bacteria are remarkably stable, facilitating microbial replication and preventing exposure to host cytoplasmically-localized innate immune sensing mechanisms. To maintain the integrity of the membrane compartment, the pathogen is armed with defensive weapons that prevent loss of vacuole integrity and potential exposure to host innate signaling. In this presentation, Dr.

A Patient-Scientist’s Road Toward Primary Prevention in Genetic Prion Disease

December 4, 2019 - 3:00pm to 4:00pm
Sonia Vallabh, J.D., Ph.D. & Eric Minikel, Ph.D., Broad Institute of MIT and Harvard

Prion disease is a rare, exceptionally rapid neurodegenerative disease. The average patient dies within only six months of their first symptom. There is no treatment that can prevent or slow this catastrophic decline. But in the lab, prion disease is among the most tractable brain diseases: It can be faithfully modeled in animals; it is caused by a single protein; and there are excellent proofs of concept that lowering the amount of that protein should protect against disease.

We Are What We Eat: Nutrition, Genes, Cognition & Deep Learning in Age-Related Macular Degeneration

December 11, 2019 - 3:00pm to 4:00pm
Emily Y. Chew, M.D., National Eye Institute

Age-related macular degeneration (AMD) is the leading cause of blindness in the United States and in the developed world. Two NIH-supported randomized clinical trials with 10 years of follow-up in nearly 10,000 participants demonstrated that nutritional supplements with antioxidant vitamins and minerals reduces the risk of progression to late AMD.

You Want to Quantify That?! The Science and Metrics of Partner Engagement in Research

December 18, 2019 - 3:00pm to 4:00pm
Melody Goodman, Ph.D., New York University

Although stakeholder engagement is a crucial part of participatory public health research, the measurement of that engagement in research is varied, inconsistent, and not methodologically sound. Dr. Goodman is pioneering new, comprehensively validated quantitative measures of stakeholder engagement. Emerging data suggest a valid and reliable measure that can be used to determine the level of research engagement and accurately assess associations between research outcomes and stakeholder engagement.

A two act play: The character of cells and the role of biomechanics

January 29, 2020 - 3:00pm to 4:00pm
Gilda A. Barabino, Ph.D., The City College of New York

Dr. Barabino’s research interests are primarily focused on cellular and tissue responses to fluid mechanical forces in the context of vascular disease and orthopedic tissue engineering. She concentrates on the characterization and quantification of mechanical and biochemical cues that influence tissue growth and disease progression.

Deciphering cancer genomes and networks

February 5, 2020 - 3:00pm to 4:00pm
Mona Singh, Ph.D., Lewis Sigler Institute for Integrative Genomics at Princeton University


The page was last updated on Thursday, October 10, 2019 - 9:45am